

State of California—Health and Human Services Agency California Department of Public Health



Office of AIDS (OA)
PrEP Assistance Program (PrEP-AP)

Management Memorandum
Memorandum Number: 2023-03

DATE: June 23, 2023

TO: Prep-ap Clinical Network Providers and Prep-ap enrollment

WORKERS

SUBJECT: ADDITION OF MEDICATIONS TO TREAT SEXUALLY TRANSMITTED

INFECTIONS (STIs) TO THE PrEP-AP FORMULARY

Effective May 25, 2023, the following STI medications have been added to the PrEP-AP formulary: tinidazole, levofloxacin, podofilox, and sinecatechins. The addition of the four STI medications are consistent with <u>2021 CDC STI Treatment Guidelines.</u>

Tinidazole is an oral antiprotozoal that is used to treat trichomoniasis, giardiasis, amebiasis, and bacterial vaginosis. Levofloxacin is a quinolone antibiotic that can used as an alternative to doxycycline in the treatment of chlamydia and as a treatment for acute epididymitis that is caused by enteric bacteria. Podofilox is a topical antiviral that is used to treat anogenital warts. Sinecatechins ointment is used as a treatment for anogenital warts.

STIs including trichomoniasis, genital warts, chlamydia, gonorrhea, and syphilis are common infections that can cause significant morbidity if not diagnosed and adequately treated. STIs have also increased significantly in California. For example, gonorrhea infections have increased by 211% from 2014 to 2018. Rapid diagnosis of STIs and access to recommended treatment is critical to improving an individual's health and preventing further STI transmission.

PrEP-AP requests that you share this information with your clinical leadership team and local prescribers. The Prep-AP formulary has been updated to reflect the addition of these medications.

If you have any questions regarding this new PrEP-AP benefit, please email PrEP-AP at PrEP.Support@cdph.ca.gov.

Thank you,

Joseph Lagrama
ADAP Branch Chief

California Department of Public Health